Senti Biosciences Holdings Inc (SNTI) — Titan Protect Analysis

SNTI

Senti Biosciences Holdings Inc

Healthcare · ·

$0.96

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$31M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.05

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$12.00

+1144% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About Senti Biosciences Holdings Inc

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell thera

https://www.sentibio.com

Country: United States Employees: 39 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.379

Positive but modest risk-adjusted returns

Kelly Fraction

0.0513

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

-0.459

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-42.4%

Historical annualised return based on price data

Max Drawdown

-92.3%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

101

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.10

Significantly more volatile than the market

52W High

$3.88

75% below the year high

52W Low

$0.77

25% above the year low

Avg Volume

179,052

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.46

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

516.93

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

-71,362.5%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$38,000

Total revenue over the last 12 months

Net Income

$-51,547,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$15.00

Target Median

$12.00

Target Low

$6.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go